← All stocks

Roivant Sciences Ltd.

ROIV Scheduled selling only

CIK 0001635088 #653 in the set updated 21 Sep 2026

Bought (1 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (1 mo)

$13.63M

$399.38K on a plan · $13.23M straight out of an exercise

Sold at will

$0.00

0 of 8 sales

Net

−$13.63M

$0.00 against sales at will

By person

15 insiders · 8 transactions

929×

Matthew Gline holds 929 times base salary in stock. $673.89M of shares against $725.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Matthew Gline last reported holding, valued at $40.45, the price Common Shares was last bought or sold at on the open market here, on 15 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Venker Eric

President & Immunovant CEO

—

$7.15M (2) scheduled

−$7.15M

1,599,154

0.2214%

$64.69M

+154.5%

Sukhatme Mayukh

President & CIO

—

$5.28M (1) scheduled

−$5.28M

18,630,739

2.58%

$753.61M

−17.2%

Fitzgerald Meghan

Director

—

$1.00M (3) scheduled

−$1.00M

41,162

0.0057%

$1.67M

+40.1%

Epperly Melissa B,

Director

—

$196.23K (2) scheduled

−$196.23K

14,954

0.0021%

$604.89K

−58.9%

Ramaswamy Vivek

10% owner

—

47,011,612

6.51%

$1.90B

−12.0%

Gold Daniel Allen

Director

—

22,654,981

3.14%

$916.39M

−67.4%

Gline Matthew

CEO

—

16,659,945

2.31%

$673.89M

−9.0%

MANCHESTER KEITH S

Director

—

15,442,623

2.14%

$624.65M

−60.6%

QVT Financial LP entity

Director by Deputization

—

13,689,166

1.90%

$553.73M

−76.0%

Torti Frank

President and Vant Chair

—

13,536,202

1.87%

$547.54M

—

Pulik Richard

CFO

—

271,810

0.0376%

$10.99M

−5.2%

Kumar Rakhi

Chief Accounting Officer

—

162,306

0.0225%

$6.57M

−22.5%

Oren Ilan

Director

—

123,680

0.0171%

$5.00M

+29.4%

MOMTAZEE JAMES C

Director

—

111,959

0.0155%

$4.53M

+21.1%

Humes Jennifer

Chief Accounting Officer

—

109,782

0.0152%

$4.44M

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

Fitzgerald Meghan

15 Sep 2026

Director

Sold on a plan

400

$40.45

$16.18K

Fitzgerald Meghan

15 Sep 2026

Director

Sold on a plan

4,712

$39.68

$186.97K

Epperly Melissa B,

15 Sep 2026

Director

Sold on a plan

600

$40.38

$24.23K

Epperly Melissa B,

15 Sep 2026

Director

Sold on a plan

4,338

$39.65

$172.00K

Fitzgerald Meghan

8 Sep 2026

Director

Sold after exercise

20,000

$39.90

$798.00K

Venker Eric

28 Aug 2026

President & Immunovant CEO

Sold after exercise

33,818

$36.44

$1.23M

Venker Eric

28 Aug 2026

President & Immunovant CEO

Sold after exercise

166,182

$35.63

$5.92M

Sukhatme Mayukh

21 Aug 2026

President & CIO

Sold after exercise

144,756

$36.48

$5.28M

Roivant Sciences Ltd.

By person

Individual transactions

What was left out